Eighty-three patients with serious urinary tract infections were treated with oral ciprofloxacin. Of these patients, 79 were hospitalized, and 41 had known structural or neurologic abnormalities of the urinary tract.
Ciprofloxacin is a fluoroquinolone antimicrobial agent. The fluoroquinolones are a group of new drugs which were derived from nalidixic acid; chemical modification has resulted in enhanced in vitro activity and better absorption after oral administration (7, 12, 26) . This study analyzed the efficacy and safety of ciprofloxacin in the treatment of 83 patients with serious urinary tract infections.
MATERIALS AND METHODS
Patients. A total of 83 adult patients with normal renal function (serum creatinine, s1.5 mg/dl) and symptomatic urinary tract infections (2 with bacteremia) were included in this study; 6 of the patients were healthy, young (19 to 30 years old; mean, 23 years) females who required hospitalization because of acute severe pyelonephritis. The other 77 patients were generally older (20 to 85 years old; mean, 56 years) with significant underlying diseases. Among the latter group, 28 were male and 49 were female; 41 had neurogenic bladders, vesicoureteral reflux, calculi, or obstructive lesions, 17 were diabetic, and 38 required intermittent or indwelling urinary catheters; and 73 required hospitalization for their infections or were hospitalized for other physical illnesses when treatment was initiated.
The diagnosis of urinary tract infection was based on the presence of signs and symptoms suggestive of urinary tract infection, the presence of pyuria and bacteriuria observed by urinalysis or Gram stain of a centrifuged urine specimen reliably obtained by catheter or the clean-catch method, and a urine culture which contained 2104 CFU of a recognized urinary pathogen or pathogens per ml (13, 18, 23 (15) . Breakpoints for defining susceptibility to ciprofloxacin were .1 ,ug/ml, susceptible; c2 ,ug/ml, moderately susceptible; and -4 ,uglml, resistant (2) . Breakpoints for defining susceptibility to other antimicrobial agents were based on recommendations of the National Committee for Clinical Laboratory Standards (15) .
RESULTS
Among the 83 patients entered into the study, 15 were excluded from analysis of efficacy (but not safety) for the following reasons: lost or negative pretreatment urine cultures from 4 patients, inadequate follow-up for 2 patients, administration of nonprotocol antibiotics or other protocol violations in 7 patients, and adverse reactions (nausea and vomiting) on day 1 of treatment in 2 patients.
Patients who were able to be evaluated included 57 who completed their courses of treatment (5 to 17 days; mean, 10 days) and 11 whose courses of treatment were abbreviated (1 day [1 dose] to 14 days; mean, 5 days) because of adverse reactions (6 patients), dispensing errors (2 patients), death from unrelated causes (2 patients), and noncompliance (1 patient The etiologic agents isolated, their susceptibilities to ciprofloxacin, and their frequencies of resistance to ceftazidime and piperacillin are shown in Table 1 . Among the 68 patients who were evaluated, 56 were infected with single pathogens, and 12 were infected with two or more pathogens. All the isolates were susceptible to s2 ,ug of ciprofloxacin per ml, except for one strain of Enterococcus faecium.
All the patients responded symptomatically to treatment. Bacteriologic outcomes are shown in Table 2 . All pathogens were eradicated by days 3 to 5 of treatment in all patients. Five patients relapsed (two had abbreviated courses of therapy) posttreatment. Organisms which recurred included Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis, and E. faecium; MICs were the same as pretreatment values. Asymptomatic colonization with yeasts occurred in six patients during treatment; the urine of one of these patients also grew Acinetobacter iwoffii (MIC, 2 ,tg/ml) on the last day of treatment.
Bacterial reinfections occurred 5 to 9 days posttreatment in seven patients. In all cases of relapse, superinfection, and reinfection, patients had neurologic bladders, structural genitourinary abnormalities, or urinary catheters.
Adverse reactions observed among the 83 patients are Reinfection at 5 to 9 days post-6 (11) 1 ( 1)" treatment a n = 9. Two patients died from unrelated causes before the 5-to 9-day follow-up. shown in Table 3 . Nausea (2%), nausea and vomiting (6%), headache (4%), and mild elevation of hepatic enzymes (2%) were probably drug related. Complaints of diarrhea, nervousness, aching legs, and blurred vision were not associated with objective findings and were of equivocal significance. Several serious reactions which were observed but which were probably not related to ciprofloxacin included a seizure associated with hypotension caused by an arrhythmia and leukopenia associated with cyclophosphamide or radiation therapy. DISCUSSION Typical MICs of ciprofloxacin are .0.06 ,ug/ml for members of the family Enterobacteriaceae, 0.13 to 0.5 pg/ml for staphylococci and P. aeruginosa, and 0.5 to 2 ,ug/ml for streptococci and enterococci (3, 6) . Observed concentrations in serum after oral ciprofloxacin readily exceed these MICs. Doses of 250, 500, and 750 mg resulted in mean peak concentrations in serum of approximately 1.4, 2.7, and 3.8 ,ug/ml, respectively, with a terminal half-life of approximately 4 to 5 h in healthy volunteers. Between 30 and 45% of orally administered drug was recovered in urine 0 to 12 h after administration, and mean concentrations in samples collected 0 to 2 h after doses of 250-, 500-, or 750-mg tablets were 205 to 846 ,ug/ml (10) .
Early clinical studies indicated that oral ciprofloxacin is effective in various types of infections, including urinary, skin, soft tissue, bone, respiratory, and intra-abdominal infections (1) . Individual reports of patients with urinary tract infections have indicated that ciprofloxacin (4, 5, 8, 9, 11, 14, 17, 20, 22, 25) , as well as other fluoroquinolones (16, 24) , are effective in treating these infections, which are caused by a variety of pathogens.
In the present study of patients with serious urinary tract infections, bacteriuria was eradicated in 100% of 68 patients. Most of the patients were hospitalized with serious, complicated infections which were often caused by pathogens resistant to ceftazidime or piperacillin or both. All five patients who relapsed 5 to 9 days posttreatment had underlying urologic diseases requiring catheterization and were treated for only 2 to 10 days (mean, 6.8 days); more prolonged treatment in these patients may have been more effective in eradicating their infections. Among the six patients who became colonized with yeasts during treatment and the seven patients who became reinfected with new organisms 5 to 9 days posttreatment, the lack of permanent cure was undoubtedly host related rather than drug related. VOL. 31, 1987 ANTIMICROB. AGENTS CHEMOTHER.
With nalidixic acid, the emergence of bacterial resistance was observed in some patients treated for urinary tract infections (19) . In the laboratory, ciprofloxacin was less likely than nalidixic acid and no more likely than mezlocillin, cefotaxime, or amikacin to select resistant mutants among 30 isolates of commonly encountered members of the Enterobacteriaceae and P. aeruginosa (21) . In vivo, emergence of resistance to ciprofloxacin, particularly with P. aeruginosa, has been observed among patients with tissue infections that are difficult to eradicate (5, 9, 22; R. J. Fass, J. Antimicrob. Chemother., in press), but it was not observed in this or other studies (9, 22) among patients with urinary tract infections.
Oral ciprofloxacin is well tolerated; the most common adverse experiences have included gastrointestinal and central nervous system reactions (1) . In the present study, nausea, vomiting, and headache were the symptoms most commonly observed and responsible for premature discontinuation of treatment. Although I could not exclude ciprofloxacin as a contributory factor, other neurologic symptoms were probably caused by unrelated underlying problems. Adverse reactions tended to occur more frequently among patients receiving 1.5 g/day than among those receiving 1.0 g/day. Lower doses have also been effective in treating urinary tract infections (4, 14, 25) and might be associated with a lower incidence of adverse reactions.
Overall, I considered ciprofloxacin to be effective and safe in the treatment of serious urinary tract infections. Because the concentrations of the drug in urine exceed the MICs for virtually all potential urinary pathogens (3, 6) , it should be most useful for treating infections caused by multiresistant organisms.
